Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Filter By:

Search by Keyword (disease, investigator, treatment name):

A Study of miRNA 371 in Patients with Germ Cell Tumors

Urologic

This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

Disease Sites: Urologic

Phase: N/A

Investigator: Davis, Nancy

NCTID: NCT04435756

Protocol No: SWOGUROS1823

Learn More

Evaluation of Immunologic Response following COVID-19 Vaccination in Children, Adolescents, and Young Adults with Cancer

Pediatrics

This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the bodys immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the bodys natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and number of vaccine doses or boosts (extra vaccine shots) may strengthen or diminish the bodys protective immune response. This study may help researchers learn more about how the bodys immune system responds to the COVID-19 vaccine when the vaccination is given during or after cancer treatment.

Disease Sites: Pediatrics

Phase: N/A

Investigator: Esbenshade, Adam

NCTID: NCT05228275

Protocol No: COGACCL21C2

Learn More

Long Term Follow-up for Early Detection of Lung Cancer in Current or Former Smokers

Lung

This research trial studies the long term follow-up for early detection of lung cancer in current or former smokers. Following up on smokers by collecting and analyzing specimens in the laboratory, performing chest computed tomography (CT) scans, as well as reviewing medical records may help doctors detect lung cancer at an earlier stage.

Disease Sites: Lung

Phase: N/A

Investigator: Grogan, Eric

NCTID: NCT03181256

Protocol No: VICCTHO1730

Learn More

A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma

Multiple Cancer Types

This will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an
Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or
non-Hodgkin lymphoma. MT-0169 is an investigational drug that recognizes and binds to the
CD38 receptor, which may be found on the surface of multiple myeloma and non-Hodgkin lymphoma
cancer cells. It delivers a dose of a modified toxin that kills these cells.

Disease Sites: Multiple Myeloma, Phase I

Phase: I

Investigator: Dholaria, Bhagirathbhai

NCTID: NCT04017130

Protocol No: VICCHEMP1975

Learn More

Vincristine Pharmacokinetics in Infants

Pediatrics

This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children. Vincristine is an anticancer drug used to a variety of childhood cancers. The doses anticancer drugs in children must be adjusted based on the size of the child because children vary significantly in size (height, weight, and BSA) and ability to metabolize drugs from infancy to adolescence. The dose of most anticancer drugs is adjusted to BSA, which is calculated from a patients weight and height. However, infants and young children have more severe side effects if the BSA is used to calculate their dose, so new dosing models have to be made to safely give anticancer drugs to the youngest patients. This new method uses a BSA-banded approach to determine the dose. Collecting blood samples before and after a dose of the drug will help researchers determine whether this new vincristine dosing method results in equivalent drug levels in the blood over time in infants and young children compared to older children.

Disease Sites: Pediatrics

Phase: N/A

Investigator: Borinstein, Scott

NCTID: NCT05359237

Protocol No: COGPEPN22P1

Learn More

The COVID-19 and Cancer Consortium (CCC19) Registry

Miscellaneous

Disease Sites: Miscellaneous

Phase: N/A

Investigator: Not Available

NCTID: NCT04354701

Protocol No: VICCMD2032

Learn More

Studying Health Outcomes after Treatment in Patients with Retinoblastoma, RIVERBOAT Study

Multiple Cancer Types

This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma.

Disease Sites: Pediatrics, Retinoblastoma (Pediatrics)

Phase: N/A

Investigator: Friedman, Debra

NCTID: NCT03932786

Protocol No: VICCPED1878

Learn More